Celgene Announces EC Approval for ABRAXANE Plus Gemcitabine for Treatment of Metastatic Pancreatic Cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG ), today announced that the European Commission (EC) has granted approval for ABRAXANE (paclitaxel formulated as albumin